Macrogen has pioneered genome sequencing and testing in Korea, becoming a reference company and supporting the development of technology in the country. However, it would be wrong to limit Macrogen's ...

Bernstein analyst Eve Burstein lowered the firm’s price target on Illumina (ILMN) to $140 from $145 and keeps a Market Perform rating on the ...

Illumina has begun rolling out a series of updates to its top-of-the-line DNA sequencer models, with the goal of making the ...

Illumina, Inc. ILMN has announced a series of updates to its NovaSeq X Series. The company’s single-flow-cell NovaSeq X Sequencing System is now available for the first time, alongside the software v1 ...

ClariMed, Inc., a global leader in human-centered medical device development and regulatory services, has announced the ...

MAIA Biotechnology, Inc., ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that it has entered into a clinical supply ...

Illumina (ILMN) announced a series of updates to its NovaSeq X Series, delivering the NovaSeq X single-flow-cell system alongside a software ...

Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced a series of ...

Read Our Latest Stock Analysis on Illumina Illumina Trading Down 0.9 % Illumina stock opened at $143.12 on Wednesday. Illumina, Inc. has a 52-week low of $100.08 and a 52-week high of $156.66. The ...

How Illumina's Erin Imsand and her team helped ... about a project still in the concept stage-what would become the NovaSeq X. She was asked to help incorporate lyophilization (better known ...